

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

NCT07021209

Status	RECRUITING
Phase	Phase 1
Sponsor	Grit Biotechnology
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (3)

- Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
- Expected survival period > 12 weeks.
- Any previous systemic treatment must have undergone at least 4 weeks or 5 half lives (whichever is shorter) by the time the participant plans to receive the study treatment.

Exclusion (3)

- History of organ transplantation, splenectomy, and allogeneic or autologous stem cell transplantation.
- History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.
- Received systemic corticosteroids at a dose of ≥ 10 mg/day prednisone equivalent within 7 days prior to GT719 infusion, except for inhaled corticosteroids.

Locations (1 total)

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China